Icterus Clinical Trial
Official title:
Influence of Cholestasis on Intestinal BCRP Expression
The expression of transporters involved in bile acid homeostasis is differentially regulated during obstructive cholestasis. Bile acids are also substrates of the drug efflux transporter breast cancer resistance protein (BCRP) that is highly expressed in the human intestine. Therefore we intend to analyze whether intestinal BCRP expression could be altered during cholestasis.
BCRP is capable of transport bile acids and may indicate that this transporter is involved
in bile acid homeostasis. As an efflux pump, it could protect the enterocytes from potential
toxic bile acid concentrations. During cholestasis, where the enterohepatic circulation is
disrupted, there occurs an adaptive regulation of transporters for bile acids, bilirubin and
cholesterol. These changes take place in liver, kidney, as well as in the intestine.
Using real-time RT-PCR analysis we determine BCRP mRNA expression levels in duodenal tissue
of healthy subjects and cholestatic patients. BCRP protein levels will be determined by
immunohistochemistry.
Healthy subjects and cholestatic patients are enrolled in the study after giving informed
consent. Control subjects with an indication for a gastrointestinal tract endoscopy within a
cancer-screening program and patients with obstructive cholestasis with an interventional
endoscopic retrograde cholangiopancreatography (ERCP) are included in this study. During
endoscopy four biopsy specimens are obtained from the distal part of the duodenum. Biopsies
are immediately stored at –70°C until further processing.
;
Observational Model: Defined Population, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05718349 -
FGF19 in Obstructive Cholestasis: "Unveil the Signal"
|